Everybody knows where is the biggest Pharmaceutical market, definitely India. No doubt, CPHI & P-MEC India is the key to open this amazing India gate. It was my pleasure to join in this show and build up CVC and Changsung collaboration. See you in 2025 again, please remain a piece of Tandoori chicken for me. 😀
📢 We are thrilled to announce a significant milestone in our mission to improve the lives of patients suffering from Osteoarthritis. Our partner, Hansoh Pharma (Jiangsu Hansoh Pharmaceutical Group Co., Ltd.), has successfully initiated the clinical trial for KioMedine-vs-one in China. This achievement marks a crucial step towards bringing our innovative treatment to over 100 million Osteoarthritis patients in the region. We extend our gratitude to the dedicated teams at KiOmed Pharma and Hansoh Pharma for their work in reaching this pivotal stage. 👏 🔗 For more details on this development and its implications for Osteoarthritis treatment in China, please read our full press release: https://lnkd.in/eyxm8Yf5 #HealthTech #BiotechInnovation #ClinicalResearch #OsteoarthritisTreatment #ClinicalTrials #KiOmedPharma #Chitosan
India continues to strengthen its position as a global pharmaceutical leader. During the iPHEX 2024 event, the director general of Pharmexcil, K Raja Bhanu, highlighted the remarkable growth in Indian pharmaceutical exports, which surpassed $27.9 billion in FY24, a 90% rise from FY14. This reinforces India’s vital role in supplying generic medicines globally, contributing significantly to healthcare systems, particularly in the U.S. where Indian generics have saved over $200 billion. India’s pharma industry is also making strides in innovation, exemplified by the development of NexCAR19, the country’s first indigenous CAR-T cell therapy. On the international front, Merck made a key announcement on 2nd September 2024 regarding its Phase III clinical trial for cladribine capsules (MyClad) in treating generalized Myasthenia Gravis (gMG). This study aims to explore the efficacy and safety of the oral treatment, potentially offering a new option for managing this autoimmune disease, which affects the neuromuscular junction. #pharmatreds #indianpharmaindustry #PharmaTalk #PharmaEducation #PharmaIndustry #HealthcareInnovation #PharmaCareers #ClinicalResearch #PharmaUpskilling #PharmaTraining #PharmaStudents #STEMEducation #PharmaSkills #PharmaOpportunities #RegulatoryAffairs #MedicalWriting #PharmaLeadership #PharmaGrowth #PharmaCommunity #PharmaFuture
"Exciting times ahead! 🌟 Join CHROMOSEP at CPHI Milan 2024, where innovation meets excellence in the heart of Italy. Meet our experts Shailendra Gupta, Paras Shah, and Darshit Shah at Stand #6SU81 from 8th to 10th October 2024 at Fiera Milano. Let’s explore cutting-edge solutions in pharmaceutical advancements together! 💡 visit us! #CPHIMilan #CHROMOSEP #PharmaInnovation #FieraMilano #MeetTheExperts #PharmaExcellence #CPHI2024"
This week's Pearce IP #BioBlast features the following (and more!): - #aflibercept: Court temporarily restrains US launch of Mylan’s/Biocon’s #Eylea® (aflibercept) biosimilar - #aflibercept: MS PHARMA & Klinge Pharma partner to commercialise Formycon AG’s aflibercept biosimilar in MENA - #bevacizumab: Outlook Therapeutics, Inc. submits UK MAA for first ophthalmic bevacizumab - #adalimumab: Second Quallent Pharmaceuticals Health, LLC deal for US adalimumab distribution – BI follows Alvotech - Novo Nordisk Releases Positive Clinical Trial Results for Mim8 - #liraglutide: Cipla targets Nov 24 launch for liraglutide biosimilar in PTE challenge against Novo Nordisk - #eculizumab: Alexion Pharmaceuticals, Inc. US preliminary injunction against Samsung Bioepis rejected for eculizumab Read more: https://lnkd.in/gfkeMauC #BioBlast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma #lifesciences #femalefounder
#chemicals#laboratory chemicals#pharmceuticals #exibition CPHI&PMEC India 2024 CPHI & PMEC India expo,an event which is scheduled for 26-28 November 2024,at india expo center,Greater Noida (UP),Delhi-NCR.This is the 17th edition. People from the pharmaceutical, chemicals industry etc will participate as well as exhibit their products and services. It is a critical platform for business expansion and industry insights.This expo is a renowned hub for thought leadership and industry evolution.There will be a two day summit where global experts will discuss next-generation therapeutics, the growing role biosimilars, and the impact of digital transformation on pharma. India pharmaceutical awards will also be held. This is a must attend event for anyone looking to be part of the next wave of pharmaceutical innovations.Here, unique opportunities are offered to connect, learn and grow. (for details pls visit informa markets india Pvt ltd. The article is based on newspapers and experience. Use your own diligence, prudence and verify information before visiting there.)
We are pleased to share that the webinar series organized by Together for Rare Diseases & ERICA, brought together over 150+ members of the rare disease research community, who had the chance to learn about the contributions and the practicalities of public-private partnerships between ERNs and pharmaceutical companies. 🤝 🗂️ 👉 To find out more about the ERNs and how they are key partners in conducting research project with industry, you can find here a recording and summary of the first webinar from December 2024 (link: https://lnkd.in/eT4735m4). Likewise, you can learn more about the contributions of the pharmaceutical industry to rare disease research in conjunction with academic partners here: https://lnkd.in/eZx3rtCW. #RareDiseases #Research #PublicPrivatePartnerships #ERICA Together for Rare Diseases
B.Pharma Student | Advance AI Knowledge | Exploring Pharma-Tech Synergies| Internship Experience in Pharma Production and QA/QC |
🌟 Innovative strides in the Indian pharmaceutical landscape! 🌟 Pharmazz Inc., an American biopharmaceutical company, continues strengthening its foothold in India through groundbreaking collaborations and clinical advancements. 💊 Key Highlights: Centhaquine (Lyfaquin): Designed for treating hypovolemic shock, this novel drug underwent clinical trials in India and received market authorization in 2020. By November 2020, it was officially launched as Lyfaquin. 🚀 Dr. Reddy's Partnership (2024): Pharmazz partnered with Dr. Reddy's Laboratories to expand Lyfaquin's reach across the Indian market. Sovateltide (2023): In collaboration with Sun Pharma, Pharmazz introduced this innovative drug for ischemic stroke treatment, paving the way for better healthcare outcomes in the country. These partnerships highlight India's growing prominence in clinical research and its ability to bring cutting-edge therapies to patients globally. 🙌 Kudos to Pharmazz, Dr. Reddy's, and Sun Pharma for their dedication to advancing healthcare in India and beyond! 📢 Let’s celebrate these milestones and discuss how innovation shapes pharmaceuticals' future! #SunPharma #Cipla #DrReddys #LupinPharma #ZydusLife #AurobindoPharma #Biocon #TorrentPharma #GlenmarkPharma #AlembicPharma #CadilaHealthcare #Wockhardt #AlkemLaboratories #NatcoPharma #IPCA #DivisLaboratories #GranulesIndia #StridesPharma #GlandPharma #PharmaIndia #Pharmaceuticals #Innovation #Healthcare #India #Pharmazz #Collaborations
🌟 Exciting updates in the pharmaceutical world! 🌟 1. Alvotech & ADVANZ PHARMA have launched an Eylea biosimilar, providing a cost-effective option for retinal disorder treatments. 👁️💉 2. PCI Pharma Services is expanding with a new sustainable facility in Co. Meath, aiming for LEED Gold certification. 🌱🏭 3. Pyros Pharmaceuticals received FDA approval for Vigafyde, a new drug to treat infantile spasms, bringing hope to affected families. 👶✅ 4. Sanofi & Belharra Therapeutics announced a $700M partnership to develop innovative therapies for immunological disorders. 🤝💊 📌 Read more at- https://lnkd.in/dKhZfHxi #PharmaNews #HealthcareInnovation #FDAApproval #Sustainability #Biotech #MedicalResearch #PharmaNow
H224 continues to be a rewarding period for Basilea Pharmaceutica, with the announcement of a third successive milestone payment for Cresemba in the last month following strong sales performance (+24% y-o-y growth in in-market sales to US$489m for the 12 months ending March 2024). The latest milestone (US$25m/CHF21m) was triggered by license partner Pfizer exceeding a predetermined sales threshold in Europe. In total, Cresemba has raked in upwards of CHF34m in milestone payments in the year to date (with c CHF32m in H224 thus far), and Edison Group expects a further c CHF5m before year-end based on the most recent guidance from management. Beyond Cresemba, Edison expects the key focus areas for Basilea in H224 to be finalising a US commercialisation partner for Zevtera and the initiation of the first Phase III study for fosmanogepix (in candidemia/invasive candidiasis). #biopharmaceuticals #medical #sustainablegrowth https://lnkd.in/dKdm4GHV
